|Bid||2,379.20 x 0|
|Ask||2,385.40 x 0|
|Day's Range||2,361.00 - 2,400.00|
|52 Week Range||2,201.20 - 3,323.00|
|PE Ratio (TTM)||59.85|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Barely four months into her tenure as chief executive of GlaxoSmithKline, Emma Walmsley is showing her determination to focus the pharmaceutical company's research and development efforts. Having said ...
Ionis Pharmaceuticals (IONS) will independently develop Inotersen and IONIS-FB-L Rx as GlaxoSmithKline declines its option on both drugs.
GlaxoSmithKline PLC (GSK), Simon Property Group Inc (SPG), GGP Inc (GGP), and CenturyLink Inc (CTL) have declined to their respective three-year lows.